Shi W Y, Xie L X
Shandong Eye Institute, Qingdao 266071, China.
Zhonghua Yan Ke Za Zhi. 2016 Mar;52(3):161-3. doi: 10.3760/cma.j.issn.0412-4081.2016.03.001.
Corneal disease ranks second among blinding diseases in China, with the corneal blindness taking up one fourth of the blind population. It has a high incidence and a low rate of sight rehabilitation. The lack of cornea donors and the shortage of corneal specialists have become the bottleneck that hampers the development in curing corneal disease. It is of primal importance to find sufficient donor sources in order to alleviate the current situation. In 2015, the world's first artificial bioengineered cornea was approved by CFDA to be applied clinically as a substitute for human cornea in lamellar keratoplasty. It will not only relieve the cornea donor shortage, but will also spur the training and practices of corneal specialists. The application and clinical trials of such an innovative product will significantly boost fundamental and clinical researches in corneal disease in our country, helping more patients with corneal blindness to recover their sights.
角膜病在中国致盲性眼病中位居第二，角膜盲占盲人总数的四分之一。其发病率高，视力康复率低。角膜供体缺乏和角膜专科医生短缺已成为阻碍角膜病治疗发展的瓶颈。寻找充足的供体来源以缓解当前状况至关重要。2015年，全球首个生物工程人工角膜获国家食品药品监督管理总局批准，可在临床用于板层角膜移植术替代人角膜。这不仅将缓解角膜供体短缺问题，还将推动角膜专科医生的培训与实践。此类创新产品的应用和临床试验将显著推动我国角膜病的基础研究和临床研究，帮助更多角膜盲患者恢复视力。
